AI assistant
Revolution Medicines, Inc. — Director's Dealing 2021
Jun 24, 2021
30695_dirs_2021-06-24_0ee7873c-63e6-4022-b564-87c67780cc0b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Revolution Medicines, Inc. (RVMD)
CIK: 0001628171
Period of Report: 2021-06-22
Reporting Person: Borisy Alexis (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-22 | Common Stock | A | 3617 | — | Acquired | 49718 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-22 | Stock Option (Right to Buy) | $32.93 | A | 12659 | Acquired | 2031-06-21 | Common Stock (12659) | Direct |
Footnotes
F1: Includes 3,617 Restricted Stock Units.
F2: On September 10, 2020, December 3, 2020, and February 25, 2021, Third Rock Ventures GP III, L.P. distributed 639, 639 and 43,015 shares, respectively, to the Reporting Person through in-kind, pro rata distributions without value. The distributions were exempt Section 16 of the Exchange Act pursuant to Rule 16a-9.
F3: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 22, 2021 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.